$BCRX
BIOCRYST PHARMACEUTICALS INC

2016 Q3 Form 10-Q Financial Statement

#000117184316013033 Filed on November 08, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2015 Q3
Revenue $7.763M $10.99M
YoY Change -29.34% 239.31%
Cost Of Revenue $1.346M
YoY Change
Gross Profit $7.763M $9.641M
YoY Change -19.48% 197.75%
Gross Profit Margin 100.0% 87.75%
Selling, General & Admin $2.756M $2.731M
YoY Change 0.92% 50.88%
% of Gross Profit 35.5% 28.33%
Research & Development $14.11M $20.07M
YoY Change -29.71% 53.94%
% of Gross Profit 181.7% 208.14%
Depreciation & Amortization $170.0K $50.00K
YoY Change 240.0% 25.0%
% of Gross Profit 2.19% 0.52%
Operating Expenses $16.86M $22.80M
YoY Change -26.04% 74.88%
Operating Profit -$9.241M -$13.16M
YoY Change -29.79% 13.37%
Interest Expense $1.465M $1.241M
YoY Change 18.05% 1.97%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$11.53M -$14.62M
YoY Change -21.14% 67.47%
Income Tax
% Of Pretax Income
Net Earnings -$11.53M -$14.62M
YoY Change -21.15% 67.46%
Net Earnings / Revenue -148.5% -133.08%
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$156.4K -$0.20
COMMON SHARES
Basic Shares Outstanding 73.24M
Diluted Shares Outstanding 73.73M 73.26M

Balance Sheet

Concept 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $52.82M $70.33M
YoY Change -24.89% -44.67%
Cash & Equivalents $35.39M $46.63M
Short-Term Investments $17.43M $23.70M
Other Short-Term Assets $3.600M $7.100M
YoY Change -49.3% 51.06%
Inventory $2.232M
Prepaid Expenses
Receivables $5.968M $4.300M
Other Receivables $0.00 $0.00
Total Short-Term Assets $64.63M $84.50M
YoY Change -23.51% -37.45%
LONG-TERM ASSETS
Property, Plant & Equipment $10.10M $1.146M
YoY Change 780.89% 473.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $14.40M $36.10M
YoY Change -60.11% 11933.33%
Other Assets $2.190M $5.239M
YoY Change -58.2% 249.27%
Total Long-Term Assets $26.87M $54.45M
YoY Change -50.66% 2622.7%
TOTAL ASSETS
Total Short-Term Assets $64.63M $84.50M
Total Long-Term Assets $26.87M $54.45M
Total Assets $91.50M $139.0M
YoY Change -34.15% 1.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.760M $3.782M
YoY Change -27.02% 64.43%
Accrued Expenses $10.78M $23.03M
YoY Change -53.18% 43.02%
Deferred Revenue
YoY Change
Short-Term Debt $28.10M $30.00M
YoY Change -6.33% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $51.52M $64.44M
YoY Change -20.05% 29.41%
LONG-TERM LIABILITIES
Long-Term Debt $25.30M $0.00
YoY Change
Other Long-Term Liabilities $10.60M $10.30M
YoY Change 2.91% 171.05%
Total Long-Term Liabilities $35.90M $10.30M
YoY Change 248.54% 171.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $51.52M $64.44M
Total Long-Term Liabilities $35.90M $10.30M
Total Liabilities $87.50M $74.10M
YoY Change 18.08% 37.99%
SHAREHOLDERS EQUITY
Retained Earnings -$561.6M -$492.8M
YoY Change 13.96%
Common Stock $738.0K $733.0K
YoY Change 0.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.993M $64.05M
YoY Change
Total Liabilities & Shareholders Equity $91.50M $139.0M
YoY Change -34.15% 1.35%

Cashflow Statement

Concept 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$11.53M -$14.62M
YoY Change -21.15% 67.46%
Depreciation, Depletion And Amortization $170.0K $50.00K
YoY Change 240.0% 25.0%
Cash From Operating Activities -$17.55M -$12.66M
YoY Change 38.63% 47.21%
INVESTING ACTIVITIES
Capital Expenditures -$180.0K -$150.0K
YoY Change 20.0% 400.0%
Acquisitions
YoY Change
Other Investing Activities $22.13M -$18.00M
YoY Change -222.94% -467.35%
Cash From Investing Activities $21.95M -$18.14M
YoY Change -221.0% -472.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.33M 640.0K
YoY Change 3389.06% -81.07%
NET CHANGE
Cash From Operating Activities -17.55M -12.66M
Cash From Investing Activities 21.95M -18.14M
Cash From Financing Activities 22.33M 640.0K
Net Change In Cash 26.73M -30.16M
YoY Change -188.63% 8517.14%
FREE CASH FLOW
Cash From Operating Activities -$17.55M -$12.66M
Capital Expenditures -$180.0K -$150.0K
Free Cash Flow -$17.37M -$12.51M
YoY Change 38.85% 45.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 bcrx Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
14371000
CY2015Q4 bcrx Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
28395000
CY2016Q3 bcrx Available For Sale Securities Debt Maturities Maturing After Two Years
AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears
bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
499000
bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
459000
CY2016Q3 bcrx Available For Sale Securities Accrued Interest
AvailableForSaleSecuritiesAccruedInterest
68000
CY2015Q4 bcrx Available For Sale Securities Accrued Interest
AvailableForSaleSecuritiesAccruedInterest
293000
CY2015Q4 bcrx Available For Sale Securities Debt Maturities Maturing After Two Years
AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears
19288000
CY2016Q3 bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
4262000
CY2015Q3 bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
5162000
bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
11350000
bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
35643000
CY2016Q3 bcrx Collaborative And Other Research And Development Revenues
CollaborativeAndOtherResearchAndDevelopmentRevenues
4262000
CY2015Q3 bcrx Collaborative And Other Research And Development Revenues
CollaborativeAndOtherResearchAndDevelopmentRevenues
5162000
bcrx Collaborative And Other Research And Development Revenues
CollaborativeAndOtherResearchAndDevelopmentRevenues
11350000
bcrx Collaborative And Other Research And Development Revenues
CollaborativeAndOtherResearchAndDevelopmentRevenues
35643000
CY2016Q3 bcrx Deferred Collaboration Expense Assets
DeferredCollaborationExpenseAssets
214000
CY2015Q4 bcrx Deferred Collaboration Expense Assets
DeferredCollaborationExpenseAssets
265000
bcrx Deferred Collaboration Expense Changes In Operating Assets And Liabilities
DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities
-43000
bcrx Deferred Collaboration Expense Changes In Operating Assets And Liabilities
DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities
117000
bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear
1889000
bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Five
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive
411000
bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour
2633000
bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree
4700000
bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo
6958000
CY2016Q3 bcrx Lease Financing Obligation Net Of Current
LeaseFinancingObligationNetOfCurrent
2675000
CY2015Q4 bcrx Lease Financing Obligation Net Of Current
LeaseFinancingObligationNetOfCurrent
2375000
bcrx Maturity Of Investments
MaturityOfInvestments
P3Y
CY2015Q1 bcrx Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
150000000
bcrx Number Of Stockbased Compensation Plans
NumberOfStockbasedCompensationPlans
2
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2760000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9307000
CY2016Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5968000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6243000
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10782000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16237000
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-206000
CY2016Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
564791000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
558113000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6478000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7773000
CY2016Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
116000
CY2015Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
110000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
335000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
329000
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1291000
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3821000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1190000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3673000
CY2016Q3 us-gaap Assets
Assets
91502000
CY2015Q4 us-gaap Assets
Assets
122359000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
64632000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
63794000
CY2016Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
31805000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
70347000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
27000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
212000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
70261000
CY2016Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
17434000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
22664000
CY2016Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
17434000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
22664000
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
31715000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73355000
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73758000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73355000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
47683000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7913000
CY2016Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
14371000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35387000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28899000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54540000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46627000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6488000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73758000
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
738000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
734000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11552000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14530000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50413000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24755000
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2015Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1346000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
us-gaap Cost Of Goods Sold
CostOfGoodsSold
1361000
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
17004000
CY2015Q3 us-gaap Costs And Expenses
CostsAndExpenses
24149000
us-gaap Costs And Expenses
CostsAndExpenses
57789000
us-gaap Costs And Expenses
CostsAndExpenses
65905000
CY2016Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
98000
CY2015Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
90000
CY2016Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
265000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
329000
CY2016Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2282000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2163000
CY2016Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
8480000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
9674000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
311000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
137000
CY2016Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1904000
CY2015Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
us-gaap Interest Expense
InterestExpense
3862000
CY2016Q3 us-gaap Interest Payable Current
InterestPayableCurrent
7563000
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
16591000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-21000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
CY2016Q3 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-931000
CY2015Q3 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-352000
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-6561000
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
861000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-12066000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
12582000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1075000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1602000
us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-7372000
us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-793000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
817000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-512000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
620000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-683000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-667000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-872000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-275000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1995000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-106000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1472000
CY2016Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
109000
CY2015Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
134000
us-gaap Interest And Other Income
InterestAndOtherIncome
695000
us-gaap Interest And Other Income
InterestAndOtherIncome
367000
CY2016Q3 us-gaap Interest Expense
InterestExpense
1465000
CY2015Q3 us-gaap Interest Expense
InterestExpense
1241000
us-gaap Interest Expense
InterestExpense
4356000
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
6746000
CY2016Q3 us-gaap Inventory Net
InventoryNet
2232000
CY2015Q4 us-gaap Inventory Net
InventoryNet
1612000
CY2016Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2232000
CY2015Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1612000
CY2016Q3 us-gaap Investments And Cash
InvestmentsAndCash
68698000
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91502000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
122359000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
51520000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62257000
CY2016Q3 us-gaap Line Of Credit
LineOfCredit
22665000
CY2015Q4 us-gaap Line Of Credit
LineOfCredit
us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
0
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
20972000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5392000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
33100000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-15017000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-47584000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
1712000
us-gaap Net Income Loss
NetIncomeLoss
-50641000
us-gaap Net Income Loss
NetIncomeLoss
-24884000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-11528000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-14621000
CY2016Q3 us-gaap Notes Payable Current
NotesPayableCurrent
28133000
CY2015Q4 us-gaap Notes Payable Current
NotesPayableCurrent
27804000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9241000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13162000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40419000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22250000
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2190000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5468000
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
91000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
228000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
129000
us-gaap Payments For Hedge Financing Activities
PaymentsForHedgeFinancingActivities
2190000
us-gaap Payments For Hedge Financing Activities
PaymentsForHedgeFinancingActivities
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
48343000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
5278000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1076000
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2007000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2674000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">During the first quarter of 2016, the Company adopted Accounting Standards Update No. 2015-03, <div style="display: inline; font-style: italic;">Interest &#x2013; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</div>. Accordingly, debt issuance costs of $2,196 classified as other current assets as of December 31, 2015 have been reclassified and netted against non-recourse notes payable to conform to the 2016 presentation.</div></div></div></div>
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1175000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
22658000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
38272000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
35874000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
204000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4217000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
300000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10095000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5149000
CY2016Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
5968000
CY2015Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6243000
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
11000
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
13000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14105000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20067000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48850000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53711000
CY2016Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1506000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1612000
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-561558000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-510917000
CY2016Q3 us-gaap Revenues
Revenues
7763000
CY2015Q3 us-gaap Revenues
Revenues
10987000
us-gaap Revenues
Revenues
17370000
us-gaap Revenues
Revenues
43655000
CY2016Q3 us-gaap Royalty Expense
RoyaltyExpense
143000
CY2015Q3 us-gaap Royalty Expense
RoyaltyExpense
5000
us-gaap Royalty Expense
RoyaltyExpense
247000
us-gaap Royalty Expense
RoyaltyExpense
507000
CY2016Q3 us-gaap Royalty Revenue
RoyaltyRevenue
3501000
CY2015Q3 us-gaap Royalty Revenue
RoyaltyRevenue
126000
us-gaap Royalty Revenue
RoyaltyRevenue
6020000
us-gaap Royalty Revenue
RoyaltyRevenue
1776000
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
CY2015Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
5699000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
6236000
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
7763000
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
10987000
us-gaap Sales Revenue Net
SalesRevenueNet
17370000
us-gaap Sales Revenue Net
SalesRevenueNet
43655000
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2756000
CY2015Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2731000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8692000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10326000
us-gaap Share Based Compensation
ShareBasedCompensation
6478000
us-gaap Share Based Compensation
ShareBasedCompensation
7773000
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
3993000
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73262000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73677000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72752000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div></div></div></div>
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
47724000
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73734000

Files In Submission

Name View Source Status
0001171843-16-013033-index-headers.html Edgar Link pending
0001171843-16-013033-index.html Edgar Link pending
0001171843-16-013033.txt Edgar Link pending
0001171843-16-013033-xbrl.zip Edgar Link pending
bcrx-20160930.xml Edgar Link completed
bcrx-20160930.xsd Edgar Link pending
bcrx-20160930_cal.xml Edgar Link unprocessable
bcrx-20160930_def.xml Edgar Link unprocessable
bcrx-20160930_lab.xml Edgar Link unprocessable
bcrx-20160930_pre.xml Edgar Link unprocessable
exh102_1.jpg Edgar Link pending
exh102_2.jpg Edgar Link pending
exh_101.htm Edgar Link pending
exh_102.htm Edgar Link pending
exh_103.htm Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
exh_322.htm Edgar Link pending
f10q_110816p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending